Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554192 | 0.85 | PRMT6 (0.66) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL9912161 | 0.83 | PRMT6 (0.68) | PRMT6CARM1CCR3KCNH2 | |
| SCHEMBL18782801 | 0.82 | KDM4E (0.38) | PRMT6CARM1CCR3KCNH2ALDH1A1 | |
| SCHEMBL7698046 | 0.81 | CCR3 (0.71) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL20012567 | 0.79 | ACHE (0.40) | CCR3KCNH2 | |
| SCHEMBL14930168 | 0.79 | PRMT6 (0.50) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL5640121 | 0.78 | CCR3 (0.68) | CCR3ALDH1A1SIGMAR1 | |
| SCHEMBL12041321 | 0.78 | KCNH2 (0.61) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL12041242 | 0.77 | KCNH2 (0.68) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL19364742 | 0.77 | SCD5 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | PRMT6 1733/4885CARM1 2432/4885CCR3 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.